Aurora Biomed invites you to attend
the Third Annual Ion Channel Retreat to be held in Vancouver B.C. from June 6th-8th, 2005. The mission of the conference is to encourage
scientific discourse spanning the spectrum of ion channel disciplines.
Researchers from both
academia and industry will be able to establish
connections and exchange fresh ideas to accelerate
ion channel
research, drug discovery and safety pharmacology.
The 2nd annual Ion Channel Retreat was an overwhelming success and we would
like to continue in facilitating scientific exchange amongst ion channel
researchers.
Go to Retreat Abstracts |
Topics will
include, but are not limited to:
1) Ion Channels
as Targets for Drug Discovery
2) Ion Channel Research Technologies
3) Ion Channels & Drug Safety and
4) Ion Channels & Diseases |
| Scientific Advisory Board |
Dr. Kurt
Stoeckli
Aventis
DI&A LG Global Head LDT |
Dr. Terry Snutch
Univ. of
B.C. & Neuromed Technologies
Chief Scientific Officer |
Dr. Greg Kaczorowski
Merck
Senior Director of Ion Channels |
Dr. Bernard Fermini
Pfizer
Associate Research Fellow |
Mr. David Cronk
Ionix
Group Leader, Molecular Pharmacology |
| Ion Channels as Pain Drug Discovery Targets |
Registration and Breakfast
June 6, 2005
7:30 |
Welcome
8:30
Sophia Liang
Director of Marketing,
Aurora
Biomed |
Chairperson’s Opening Remarks
8:35
Terry Snutch, Ph.D.
Chief Scientific Officer, Neuromed Technologies Inc.
Professor,
University
of
British Columbia
|
Molecular Models of Voltage-Gated Potassium and Sodium Channels with Ligands
8:40
Boris S. Zhorov, Ph.D.
Professor of Biophysics, Department of Biochemistry and Biomedical Sciences,
McMaster University |
Voltage-gated sodium Channels: Structures Implicated in
Channel
Gating
and Pharmacology
9:05
Todd Scheuer, Ph.D.
Research Associate Professor, Dept. of Pharmacology
University of Washington
 2.8 MB
|
Keynote Address
Strategies for Discovering Blockers of Voltage-gated Sodium Channels
9:30
Greg Kaczorowski, Ph.D.
Senior Director of Ion Channels, Merck
899 KB
|
COFFEE BREAK
10:10 |
Contribution of the tetrodoxin-resistant sodium channel Na 1.9 to sensory transmission and nociceptive behavior
10:40
Birgit T. Priest, Ph.D.
Primary Research Fellow, Merck Research Laboratories
875 KB
|
Voltage Gated Sodium Channels Contribute to Injury-induced
and Inherited Neuropathic Pain Syndromes
11:05
Sulayman Dib-Hajj, Ph.D.
Research Scientist, Dept. of Neurology, Center for Neuroscience &
Regeneration Medicine,
Yale
School of Medicine
2.78 MB |
New Approaches to Voltage-gated Sodium Channels and Pain
11:30
Tito Gonzalez, Ph.D.
Senior Director, Ion Transport, Vertex Pharmaceuticals
|
LUNCH
11:55 |
Ziconotide: A New Non-opioid N-type Calcium Channel Blocker for Treating Severe Chronic Pain
1:00
George Miljanich, Ph.D.
Research Fellow, Medical Affairs, Elan Pharmaceuticals |
T-type Calcium Channels as Targets for the Treatment of Pain
1:25
Neil Castle
, Ph.D.
Director of Biology, Icagen Inc.
|
| Ion Channels & Drug Safety |
Chairperson’s Opening Remarks
1:50
Bernard Fermini, Ph.D.
Associate Research Fellow, Pfizer Global Research & Development |
Keynote Address
Adverse Drug Reactions: Contribution of Ion Channels
1:55
Jean-Pierre Valentin, Ph.D.
Director Safety Pharmacology (Safety Assessment
UK
), AstraZeneca
|
The Role of Cardiac Ion Channels in Safety Pharmacology
2:35
Michael K. Pugsley, M.Sc., Ph.D.
Principal Scientist, Pharmacology, Forest Research Institute |
Coffee Break
3:00 |
Non-clinical proarrhythmia models: predicting Torsades de Pointes
3:30
Chris Lawrence, Ph.D.
Senior Scientist, Safety Assessment
UK, AstraZeneca
|
Evaluation of hERG binding and functional assays for use in cardiac safety screening
3:55
Steve Murphy, Ph.D.
Senior Scientist, Athersys, Inc. |
Ion Channel Retreat Dinner - Cloud 9
6:30
Dinner will begin at 7:00 so please gather in the hotel lobby at
6:30
so, if you are interested, we can walk as a group to the restaurant. |
|
Ion Channel Technologies |
Chairperson’s Opening Remarks
June 7, 2005
8:30
Michael Xie, Ph.D.
Associate Director, Biology, Synta Pharmaceuticals Corp. |
Keynote Address
A nonradioactive Li influx assay using Atomic Absorption Spectroscopy for identifying sodium channel modulators.
8:35
Shephali Trivedi, Ph.D.
Senior Research Bioscientist, Lead Discovery Department, AstraZeneca |
NIH
Chemical
Genomics
Center
and Future High Throughput Screening
9:15
Wei Zheng, Ph.D.
NIH, NHGRI,
NIH
Chemical
Genomics
Center
|
Cell Free Electrophysiology for High Throughput Screening of the Human
Cardiac Sodium-Calcium-Exchanger (NCX1)
9:40
Sven Geibel, Ph.D.
Lead Identification Technologies, Aventis Pharma Deutschland GmbH |
COFFEE BREAK
10:05 |
Improving the power of patch clamp – a novel drug application system improves data quality
and increases throughput
10:35
Gareth A. Jones, Ph.D.
Senior Scientist, Dept of Biology, Psychiatry Centre of Excellence for Drug Discovery, GlaxoSmithKline |
Identification of novel modulators of ion channel accessory proteins using LEPTICS®: Kv Channel Case Study
11:00
Roland Kozlowski, Ph.D.
Chief Executive Officer, Lectus Therapeutics Ltd. |
Cardiac Safety Screening: Flux Assays and in vivo Data
11:30
Sikander Gill
, Ph.D.
Director of Assay Development,
Aurora
Biomed Inc.
417 KB |
LUNCH
11:50 |
Development of a Colorimetric Method for Functional Chloride Channel Assay
1:00
Weimin Tang, Ph.D.
Principal Scientist, Johnson & Johnson Pharmaceutical Research Institute
|
Novel Antagonists of Human Kv4.3: Why Glowing Worms Make a Good Ion Channel Screen
1:25
Andrea
S. Kopke, Ph.D.
Head of Pharma Business Development, Devgen |
A knowledge-Based Strategy to Improve Ion Channel Drug Discovery
1:50
François Petitet
Aureus Pharma |
Studies on K+ channels using the Non-radioactive Rb+ Efflux Assay
2:15
Mei Ding, Ph.D.
Research Scientist, Lead Discovery Sciences, AstraZeneca R&D Mölndal |
COFFEE BREAK
2:40 |
| Ion Channels as Drug Discovery Targets |
Chairperson’s Opening Remarks
3:10
David Cronk
Head of Hit Discovery, BioFocus Discovery Ltd |
Ion Channel Drug Discovery in Non-Excitable Cells
3:15
Michael Xie, Ph.D.
Associate Director, Biology, Synta Pharmaceuticals Corp.
1.6 MB |
General Anesthetic Modulation of GABAA Receptor Function: Implications for Conformational Changes During Channel Gating
3:40
Myles Akabas, MD, Ph.D.
Associate Professor, Department of Physiology & Biophysics and Neuroscience, Albert
Einstein
College
of Medicine
745 KB |
Genetic & Functional Studies of C. elegans K+ channels: KCNQ Orthologs
4:05
Aguan Wei, Ph.D.
Research Assistant Professor of Neurobiology, Dept. of Anatomy and Neurobiology, Washington University St. Louis |
| Ion Channels and Disease |
Chairperson’s Opening Remarks
June 8, 2005
8:30
Neil Castle , Ph.D.
Director of Biology, Icagen Inc. |
Keynote Address
-
Ion channels as keys for an arrhythmia strategy
8:35
Andrea s Busch, Ph.D.
Senior VP Discovery Europe, Bayer HealthCare AG |
The First Phase I Human Gene Transfer Trial of Ion Channel Therapy for the Treatment of Erectile Dysfunction: Preliminary Results
9:15
Arnold Melman, MD
Professor & Chairman, Dept. of Urology,
Albert
Einstein
College
of Medicine |
Potassium channels: shared therapeutic target for multiple sclerosis, type-1 diabetes mellitus and rheumatoid arthritis
9:40
George Chandy
, Ph.D.
Professor, Physiology and Biophysics, UC Irvine |
Coffee Break
10:05 |
Cardiac Ion Channel Diseases: New Genes and New Mechanisms for Causing Arrhythmias.
10:35
Craig January, MD, Ph.D.
Professor of Medicine and Physiology, University of Wisconsin-Madison
|
Opportunities for drug discovery in trafficking systems and expression signals that control ion channel surface expression.
11:00
David Fedida, Ph.D.
Professor, Dept. of Physiology,
University
of
British Columbia
|
PAP-1, a selective Small Molecule Kv1.3 Blocker
11:25
Heike Wulff, Ph.D.
Medical Pharmacology and Toxicology,
University
of California
1.4 MB |
Dead Channels Walking: Physiological Silencing of Leak Conductance by Sumoylation
11:50
Steve A.N. Goldstein, MA, M.D., Ph.D.
Professor & Chair, Dept. of Pediatrics
Physician & Chief, Comer Children’s Hospital
Director, Institute for Molecular Pediatric Science |
Closing Remarks
12:15
Dong Liang, Ph.D.
President and CEO, Aurora Biomed
|
Organized Activity - Grouse
Mountain
1:30
Bus charter will leave the Hyatt at
1:30
, please gather in the hotel lobby at
1:20
so we can depart promptly |
